US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Franklin Genomic Advancements ETF

42.64

+0.78781.88%

Post-market: 42.640.00000.00%16:10 EDT

Volume:131.02K

Turnover:5.61M

Market Cap:29.85M

PE:- -

High:42.85

Open:42.26

Low:42.26

Close:41.85

52wk High:45.58

52wk Low:31.44

Shares:700.00K

Float Shares:700.00K

Volume Ratio:80.11

T/O Rate:18.72%

Dividend:0.14

Dividend Rate:0.34%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Forbion raises $2.6bn in a boost for Europe's biotech sector

Adaptive Biotechnologies Chief People Officer Francis Lo Disposes of 26,792 Common Shares Worth $770,481

Guardant Health reports COSMOS study published in Cancer Research Communications

Guardant Health Cosmos-MEL01 Study Shows Guardant Reveal Detects 81% of Distant Melanoma Recurrences

Natera, Alliance Foundation Trials Launch Phase III Navigate Breast Cancer Study Using Signatera MRD-Guided Cdk4/6 Therapy

Alliance Foundation Trials and Natera Announce Aft-70 Navigate: a Global, Randomized, Phase Iii Trial Evaluating Genentech’s Oral Selective Estrogen Receptor Degrader (Serd) with Signatera™ Mrd-Guided Cdk4/6 Inhibitor Therapy in Breast Cancer

THOMSON REUTERS

Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces First Patient Dosed in Phase 2 Clinical Trial of MAR002, a Potential Best-in-disease Investigational Therapy for the Treatment of Acromegaly

Gene Editing, Protein Electron Transfer, Self-Assembled Monolayers 鈥?Which Will Win the Nobel Prize in Chemistry? Two Experts Share Their Predictions

ADPT, MRNA, CRWV, NBIS, JAZZ trending with analysts

Natera CEO Steven Leonard Chapman Sells USD 526,544 of Common Stock

Adaptive Biotechnologies is Maintained at Buy by Guggenheim

Guardant Health price target raised to $200 from $190 at Guggenheim

Will NCCN Names MRD Test Change Adaptive Biotechnologies Stock Narrative

Simply Wall St.

Guardant Health (GH) Receives a Buy from Bernstein

Natera (NTRA) Receives a Buy from Bernstein

Natera's Signatera Genome Could Emerge as Dominant Clinical Offering Within Few Years, RBC Says

MT Newswires Live

Adaptive Biotechnologies Highlights MRD Testing Role in New Myeloma Cure Definition from International Myeloma Society

Analysts Offer Insights on Healthcare Companies: Ligand Pharma (LGND), Natera (NTRA) and Aveanna Healthcare Holdings (AVAH)

Ligand initiated with an Overweight at Barclays

US Research Roundup-Chevron, Exxon Mobil, GoDaddy

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/HELX/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"HELX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"HELX\",,,,,undefined,":{"symbol":"HELX","market":"US","secType":"STK","nameCN":"Franklin Genomic Advancements ETF","latestPrice":42.64,"timestamp":1791576000000,"preClose":41.8522,"halted":0,"volume":131015,"hourTrading":{"tag":"盘后","latestPrice":42.64,"preClose":42.64,"latestTime":"16:10 EDT","volume":1,"amount":42.64,"timestamp":1791576604044,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.01882338323911281,"floatShares":700000,"shares":700000,"eps":0,"marketStatus":"Market Closed","change":0.7878,"latestTime":"10-09 16:00:00 EDT","open":42.26,"high":42.85,"low":42.26,"amount":5613094,"amplitude":0.014097,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1791792000000},"marketStatusCode":7,"adr":0,"exchange":"CBOE","adjPreClose":41.8522,"sharesOutstanding":650000,"nav":42.701,"aum":29890376.7,"dividendRate":0.003382,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":42.64,"preClose":42.64,"latestTime":"16:10 EDT","volume":1,"amount":42.64,"timestamp":1791576604044,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":80.11190559774228,"impliedVol":0.203,"impliedVolPercentile":0.6653},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"HELX\",,,,,undefined,":{"symbol":"HELX","floatShares":700000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":80.11190559774228,"shares":700000,"dividePrice":0.1442,"high":42.85,"amplitude":0.014097,"preClose":41.8522,"low":42.26,"week52Low":31.44,"pbRate":"--","week52High":45.58,"institutionHeld":0,"latestPrice":42.64,"eps":0,"divideRate":0.003382,"volume":131015,"delay":0,"ttmEps":0,"open":42.26,"prevYearClose":36.3062,"prevWeekClose":43.79,"prevMonthClose":44.5641,"prevQuarterClose":44.5641,"fiveDayClose":43.79,"twentyDayClose":40.9874,"sixtyDayClose":39.2447},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/HELX\",params:#limit:5,,,undefined,":[{"date":"2025-12-30","symbol":"HELX","amount":0.14334,"announcedDate":"2025-12-29","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-30","defaultRemindTime":1767105000000,"name":"Franklin Genomic Advancements ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-01-08","payableDate":"2025-12-30","currency":"USD","dateTimestamp":1767070800000,"payDate":"2026-01-08"},{"market":"US","date":"2021-12-30","symbol":"HELX","amount":0.003935,"defaultRemindTime":1640874600000,"name":"FRANKLIN GENOMIC ADVANCEMENTS ETF","recordDate":"2022-01-07","payableDate":"2021-12-31","currency":"USD","type":"dividend","dateTimestamp":1640840400000},{"market":"US","date":"2021-12-13","symbol":"HELX","amount":0.114148,"defaultRemindTime":1639405800000,"name":"FRANKLIN GENOMIC ADVANCEMENTS ETF","recordDate":"2021-12-21","payableDate":"2021-12-14","currency":"USD","type":"dividend","dateTimestamp":1639371600000},{"market":"US","date":"2020-12-14","symbol":"HELX","amount":0.005005,"name":"FRANKLIN GENOMIC ADVANCEMENTS ETF","recordDate":"2020-12-23","payableDate":"2020-12-15","currency":"USD","type":"dividend","dateTimestamp":1607922000000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"HELX\",market:\"US\",,,undefined,":[{"executeDate":"2020-12-14","recordDate":"2020-12-15","paymentDate":"2020-12-23","value":0.005005,"currency":"USD"},{"executeDate":"2021-12-13","recordDate":"2021-12-14","paymentDate":"2021-12-21","value":0.114148,"currency":"USD"},{"executeDate":"2021-12-30","recordDate":"2021-12-31","paymentDate":"2022-01-07","value":0.003935,"currency":"USD"},{"executeDate":"2025-12-30","recordDate":"2025-12-30","paymentDate":"2026-01-08","value":0.14334,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"HELX\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"HELX\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1187292056","title":"Forbion raises $2.6bn in a boost for Europe's biotech sector","url":"https://stock-news.laohu8.com/highlight/detail?id=1187292056","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1187292056?lang=en_us&edition=fundamental","pubTime":"2026-10-06 20:00","pubTimestamp":1791288033,"startTime":"0","endTime":"0","summary":"This Dutch firm has completed a large fundraising round, even as European drugmakers and investors keep warning that the region's competitiveness is slipping.European pharmaceutical executives have...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HELX","WDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673806850","title":"Adaptive Biotechnologies Chief People Officer Francis Lo Disposes of 26,792 Common Shares Worth $770,481","url":"https://stock-news.laohu8.com/highlight/detail?id=2673806850","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673806850?lang=en_us&edition=fundamental","pubTime":"2026-10-06 08:13","pubTimestamp":1791245613,"startTime":"0","endTime":"0","summary":"Adaptive Biotechnologies Chief People Officer Francis Lo disposes of 26,792 common shares worth $770,481Adaptive Biotechnologies Chief People Officer Francis Lo sold 26,792 shares on Oct. 1, 2026 at U","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261006:nNDL73r6bl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Adaptive Biotechnologies Chief People Officer Francis Lo Disposes of 26,792 Common Shares Worth $770,481","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HELX","BK4121","ADPT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673085570","title":"Guardant Health reports COSMOS study published in Cancer Research Communications","url":"https://stock-news.laohu8.com/highlight/detail?id=2673085570","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673085570?lang=en_us&edition=fundamental","pubTime":"2026-10-05 23:30","pubTimestamp":1791214209,"startTime":"0","endTime":"0","summary":"Guardant Health (GH) announced Cancer Research Communications, a journal of the American Association for Cancer Research, has published results fro...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/guardant-health-reports-cosmos-study-published-in-cancer-research-communications-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/guardant-health-reports-cosmos-study-published-in-cancer-research-communications-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GNOM","FFOX","LU0889565916.HKD","LU0320765992.SGD","GNMX","PTH","GH","BK4196","EKG","BK4551","BK4535","LU0109394709.USD","GDOC","BK4588","HELX","BK4585","LFSC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673085807","title":"Guardant Health Cosmos-MEL01 Study Shows Guardant Reveal Detects 81% of Distant Melanoma Recurrences","url":"https://stock-news.laohu8.com/highlight/detail?id=2673085807","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673085807?lang=en_us&edition=fundamental","pubTime":"2026-10-05 23:27","pubTimestamp":1791214069,"startTime":"0","endTime":"0","summary":"Guardant Health COSMOS-MEL01 study shows Guardant Reveal detects 81% of distant melanoma recurrencesGuardant Health disclosed published results from a prospective, multicenter COSMOS study evaluating ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261005:nNDL5cqdWm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4196","BK4588","LFSC","GNMX","BK4551","LU0320765992.SGD","PTH","BK4535","HELX","BK4585","EKG","GH","FFOX","GNOM","GDOC","LU0889565916.HKD","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673024077","title":"Natera, Alliance Foundation Trials Launch Phase III Navigate Breast Cancer Study Using Signatera MRD-Guided Cdk4/6 Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2673024077","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673024077?lang=en_us&edition=fundamental","pubTime":"2026-10-05 20:08","pubTimestamp":1791202097,"startTime":"0","endTime":"0","summary":"Natera, Alliance Foundation Trials launch Phase III NAVIGATE breast cancer study using Signatera MRD-guided CDK4/6 therapyNatera joined Alliance Foundation Trials, Genentech to launch AFT-70 NAVIGATE,","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261005:nNDL69ccGs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2324357040.USD","LU2065170008.USD","LU1064131342.USD","LU2264538146.SGD","NTRA","LU0053671581.USD","LU2065171311.SGD","LU0012050646.USD","LU0106261612.USD","LU2065169927.USD","LU2065731478.USD","LU0345770308.USD","BK4139","LU2065171402.SGD","HELX","LU0345770993.USD","LU0963586101.USD","LU1988902786.USD","GNOM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673702177","title":"Alliance Foundation Trials and Natera Announce Aft-70 Navigate: a Global, Randomized, Phase Iii Trial Evaluating Genentech’s Oral Selective Estrogen Receptor Degrader (Serd) with Signatera™ Mrd-Guided Cdk4/6 Inhibitor Therapy in Breast Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2673702177","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673702177?lang=en_us&edition=fundamental","pubTime":"2026-10-05 20:04","pubTimestamp":1791201858,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261005:nFWN45Q02E:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0963586101.USD","LU2065171311.SGD","LU2264538146.SGD","LU0106261612.USD","LU0012050646.USD","LU1064131342.USD","LU1988902786.USD","LU2065169927.USD","BK4139","LU0345770993.USD","NTRA","LU2324357040.USD","LU0053671581.USD","GNOM","LU0345770308.USD","LU2065170008.USD","LU2065731478.USD","LU2065171402.SGD","HELX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673702771","title":"Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces First Patient Dosed in Phase 2 Clinical Trial of MAR002, a Potential Best-in-disease Investigational Therapy for the Treatment of Acromegaly","url":"https://stock-news.laohu8.com/highlight/detail?id=2673702771","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673702771?lang=en_us&edition=fundamental","pubTime":"2026-10-05 20:00","pubTimestamp":1791201600,"startTime":"0","endTime":"0","summary":"Trial follows promising MAR002 Phase 1 clinical trial results that demonstrated deep and durable IGF-1 suppression with PK properties that may enable dosing as infrequently as once every two weeks, co","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/05/3374474/18623/en/marea-therapeutics-a-subsidiary-of-lisata-therapeutics-announces-first-patient-dosed-in-phase-2-clinical-trial-of-mar002-a-potential-best-in-disease-investigational-therapy-for-the.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4551","KBWY","BK4218","BK4585","BK4007","GH","ENDO","HELX","GNMX","GDOC","BK4183","LFSC","BK4196","FFOX","LENZ","LU0109394709.USD","PTH","LU0889565916.HKD","BK4535","BK4139","EKG","BK4588","PK","BK4181","BK4539","GNOM","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146086402","title":"Gene Editing, Protein Electron Transfer, Self-Assembled Monolayers 鈥?Which Will Win the Nobel Prize in Chemistry? Two Experts Share Their Predictions","url":"https://stock-news.laohu8.com/highlight/detail?id=1146086402","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1146086402?lang=en_us&edition=fundamental","pubTime":"2026-10-04 14:50","pubTimestamp":1791096641,"startTime":"0","endTime":"0","summary":"The 2026 Nobel Prize in Chemistry will be announced on the evening of October 7, Beijing time.The Clarivate Citation Laureates list, compiled by the analytics firm Clarivate, honors researchers with...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TARK","NBDS","XT","GNOM","BMED","HELX","IDNA","DTEC","FWD","KOMP","WDNA","SYNB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672728212","title":"ADPT, MRNA, CRWV, NBIS, JAZZ trending with analysts","url":"https://stock-news.laohu8.com/highlight/detail?id=2672728212","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672728212?lang=en_us&edition=fundamental","pubTime":"2026-10-03 17:01","pubTimestamp":1791018089,"startTime":"0","endTime":"0","summary":"Analysts are intrested in these 5 stocks: ( ($ADPT) ), ( ($MRNA) ), ( ($CRWV) ), ( ($NBIS) ) and ( ($JAZZ) ). Here is a breakdown of their recent","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/weekend-updates/adpt-mrna-crwv-nbis-jazz-trending-with-analysts?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/weekend-updates/adpt-mrna-crwv-nbis-jazz-trending-with-analysts?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00BN0W2V16.EUR","LU0823416689.USD","LU0154245673.USD","BK4501","MRNX","BK4121","IE00BN0W2T93.GBP","BK4534","LU0320765992.SGD","BK4568","BK4551","WDNA","IDNA","BK4532","HELX","JAZZ","BK4533","MRNY","BK4585","BK4139","BK4007","IE00BN0W2W23.USD","LGHT","LU0154245756.USD","BK4588","LU0889565916.HKD","LU0109394709.USD","ADPT","GNOM","MRNA","BK4548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672906742","title":"Natera CEO Steven Leonard Chapman Sells USD 526,544 of Common Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2672906742","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672906742?lang=en_us&edition=fundamental","pubTime":"2026-10-03 09:35","pubTimestamp":1790991346,"startTime":"0","endTime":"0","summary":"Natera CEO Steven Leonard Chapman sells USD 526,544 of common stockNatera CEO and President Steven Leonard Chapman sold 1,273 common shares on Oct. 1, 2026 at USD 413.31.Chapman reported 96,926 Natera","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261003:nNDL7bmVKY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Natera CEO Steven Leonard Chapman Sells USD 526,544 of Common Stock","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTRA","LU2264538146.SGD","BK4139","LU2324357040.USD","LU0053671581.USD","LU0012050646.USD","HELX","LU1988902786.USD","LU2065731478.USD","LU1064131342.USD","LU2065171311.SGD","LU0345770993.USD","LU0106261612.USD","LU0963586101.USD","LU2065170008.USD","LU2065171402.SGD","LU2065169927.USD","GNOM","LU0345770308.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672104768","title":"Adaptive Biotechnologies is Maintained at Buy by Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2672104768","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672104768?lang=en_us&edition=fundamental","pubTime":"2026-10-01 22:20","pubTimestamp":1790864400,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ADPT/analyst-ratings","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","ADPT","HELX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672520357","title":"Guardant Health price target raised to $200 from $190 at Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2672520357","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672520357?lang=en_us&edition=fundamental","pubTime":"2026-10-01 20:37","pubTimestamp":1790858259,"startTime":"0","endTime":"0","summary":"Guggenheim raised the firm’s price target on Guardant Health (GH) to $200 from $190 and keeps a Buy rating on the shares. The firm adjusted its mod...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/guardant-health-price-target-raised-to-200-from-190-at-guggenheim-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/guardant-health-price-target-raised-to-200-from-190-at-guggenheim-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0109394709.USD","EKG","HELX","GNMX","BK4585","FFOX","BK4588","LU0320765992.SGD","LU0889565916.HKD","BK4196","GNOM","PTH","LFSC","BK4551","BK4535","GDOC","GH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672573956","title":"Will NCCN Names MRD Test Change Adaptive Biotechnologies Stock Narrative","url":"https://stock-news.laohu8.com/highlight/detail?id=2672573956","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672573956?lang=en_us&edition=fundamental","pubTime":"2026-10-01 10:16","pubTimestamp":1790820997,"startTime":"0","endTime":"0","summary":"Adaptive Biotechnologies reported that the updated National Comprehensive Cancer Network Multiple Myeloma Guidelines now feature a dedicated MRD testing page that recommends highly sensitive bone marrow MRD assessment using FDA-approved NGS assays, specifically naming its clonoSEQ test and outlining broader use across treatment stages.\nThe guideline shift gives Adaptive Biotechnologies a differentiated reference point in clinical practice, which could support recurring clonoSEQ testing...","market":"us","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/9551728-choice1-card/1788934355557","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/9551728-choice1-card/1788934355557"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-adpt/adaptive-biotechnologies/news/will-nccn-names-mrd-test-change-adaptive-biotechnologies-sto","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-adpt/adaptive-biotechnologies/news/will-nccn-names-mrd-test-change-adaptive-biotechnologies-sto","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ADPT","HELX","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670745514","title":"Guardant Health (GH) Receives a Buy from Bernstein","url":"https://stock-news.laohu8.com/highlight/detail?id=2670745514","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670745514?lang=en_us&edition=fundamental","pubTime":"2026-09-26 22:15","pubTimestamp":1790432125,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Eve Burstein from Bernstein maintained a Buy rating on Guardant Health, with a price target of $210.00. The company...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/guardant-health-gh-receives-a-buy-from-bernstein-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/guardant-health-gh-receives-a-buy-from-bernstein-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GNOM","FFOX","LU0889565916.HKD","LU0320765992.SGD","GNMX","PTH","GH","BK4196","EKG","BK4551","BK4535","LU0109394709.USD","GDOC","BK4588","HELX","BK4585","LFSC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670471989","title":"Natera (NTRA) Receives a Buy from Bernstein","url":"https://stock-news.laohu8.com/highlight/detail?id=2670471989","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670471989?lang=en_us&edition=fundamental","pubTime":"2026-09-26 20:25","pubTimestamp":1790425523,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Eve Burstein from Bernstein maintained a Buy rating on Natera, with a price target of $365.00. The company’s shares...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/natera-ntra-receives-a-buy-from-bernstein-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/natera-ntra-receives-a-buy-from-bernstein-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0053671581.USD","LU1064131342.USD","LU2065171402.SGD","LU0963586101.USD","LU0012050646.USD","NTRA","LU2065170008.USD","LU0106261612.USD","HELX","GNOM","LU0345770993.USD","LU2065171311.SGD","LU1988902786.USD","LU2324357040.USD","BK4139","LU2065169927.USD","LU0345770308.USD","LU2065731478.USD","LU2264538146.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670628425","title":"Natera's Signatera Genome Could Emerge as Dominant Clinical Offering Within Few Years, RBC Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2670628425","media":"MT Newswires Live","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670628425?lang=en_us&edition=fundamental","pubTime":"2026-09-25 23:30","pubTimestamp":1790350202,"startTime":"0","endTime":"0","summary":"Natera's (NTRA) Signatera Genome, the new ultra sensitive version of its molecular residual disease test, could emerge as the dominant clinical offering within a few years, RBC Capital Markets said in","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NTRA","HELX","LU2065170008.USD","BK4139","LU1988902786.USD","LU0053671581.USD","LU0345770993.USD","LU2065171402.SGD","GNOM","LU0012050646.USD","LU0106261612.USD","LU1064131342.USD","LU0963586101.USD","LU0345770308.USD","LU2324357040.USD","LU2065171311.SGD","LU2264538146.SGD","LU2065731478.USD","LU2065169927.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670447670","title":"Adaptive Biotechnologies Highlights MRD Testing Role in New Myeloma Cure Definition from International Myeloma Society","url":"https://stock-news.laohu8.com/highlight/detail?id=2670447670","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670447670?lang=en_us&edition=fundamental","pubTime":"2026-09-25 20:03","pubTimestamp":1790337803,"startTime":"0","endTime":"0","summary":"Adaptive Biotechnologies highlights MRD testing role in new myeloma cure definition from International Myeloma SocietyAdaptive Biotechnologies highlighted a new International Myeloma Society consensus","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260925:nNDL7rxcRq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","LU2095319765.USD","SG9999014039.USD","HELX","IE00BQXX3D17.EUR","SG9999014021.USD","IE00BQXX3F31.USD","BK4585","LU2210150020.SGD","IE00BN0W2T93.GBP","IE00BGHQF748.EUR","BK4112","ADPT","BK4121","IE00B3QW5Z07.USD","IE00BN0W2W23.USD","IE00BKPKM429.USD","LU2210149790.SGD","IE00BQXX3C00.GBP","SG9999014013.SGD","BK4588","LU0314104364.USD","BCDF","SG9999014005.SGD","IE00BN0W2V16.EUR","NDAQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670449564","title":"Analysts Offer Insights on Healthcare Companies: Ligand Pharma (LGND), Natera (NTRA) and Aveanna Healthcare Holdings (AVAH)","url":"https://stock-news.laohu8.com/highlight/detail?id=2670449564","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670449564?lang=en_us&edition=fundamental","pubTime":"2026-09-25 16:50","pubTimestamp":1790326207,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Ligand Pharma (LGND), Natera (NTRA) and Aveanna Heal...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-ligand-pharma-lgnd-natera-ntra-and-aveanna-healthcare-holdings-avah-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-ligand-pharma-lgnd-natera-ntra-and-aveanna-healthcare-holdings-avah-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0345770993.USD","LU0012050646.USD","LU2065171402.SGD","LU2324357040.USD","BK4196","LU0106261612.USD","NTRA","LU0053671581.USD","LABU","XLV","BK4581","LU2065169927.USD","LGND","LU2065171311.SGD","GNOM","BK4585","LU0566484027.USD","LU2264538146.SGD","BK4588","BK4139","LU1988902786.USD","LU1559883803.SGD","BK4007","LU2065170008.USD","HELX","XBI","LU2065731478.USD","LU0345770308.USD","LU1064131342.USD","BK4539","AVAH","IE0009354923.USD","LU0963586101.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670590449","title":"Ligand initiated with an Overweight at Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2670590449","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670590449?lang=en_us&edition=fundamental","pubTime":"2026-09-25 16:45","pubTimestamp":1790325913,"startTime":"0","endTime":"0","summary":"Barclays analyst Glen Santangelo initiated coverage of Ligand (LGND) with an Overweight rating and $345 price target The firm says Ligand is “diffe...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/ligand-initiated-with-an-overweight-at-barclays-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/ligand-initiated-with-an-overweight-at-barclays-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1559883803.SGD","HELX","LGND","IE0009354923.USD","BK4007","BK4139","LU0566484027.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670412443","title":"US Research Roundup-Chevron, Exxon Mobil, GoDaddy","url":"https://stock-news.laohu8.com/highlight/detail?id=2670412443","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670412443?lang=en_us&edition=fundamental","pubTime":"2026-09-25 14:58","pubTimestamp":1790319529,"startTime":"0","endTime":"0","summary":"US RESEARCH ROUNDUP-Chevron, Exxon Mobil, GoDaddySept 25 (Reuters)-Wall Street securities analysts revised their ratings and price targets on several US-listed companies, including Chevron, Exxon Mobi","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260925:nL4N45H0CH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LMRI","AXGN","ANDG","AEE","CGEM","XLP","MMM","DRI","GEN","FUL","CRL","OBK","NTRA","OKTA","ALM","META","HELX","EMR","OILT","COST","KNF","PYPL","STZ","UGE","CF","SO","AKAM","CPT","KMX","GPOR","CVX","GDDY","P","RSPC","FFBC","CRK","GXPE","FSTA","TRUC","CDNL","BNY","CMCSA","DMRA","XOM","ACAD","CNK","INFQ","UPW","GRAL","TRUN"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":2,"totalSize":200,"code":"91000000","status":"200"}]}}